Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: SIX Swiss Ex
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Large Pharma

Roche Holding AG

+ Add to Watchlist

RO:SW

258.25 CHF 3.25 1.24%

As of 11:43:39 ET on 03/05/2015.

Snapshot for Roche Holding AG (RO)

Open: 256.75 Day's Range: 253.75 - 258.25 Volume: 22,249
Previous Close: 261.50 52wk Range: 240.00 - 290.00 1-Yr Rtn: +4.25%

Stock Chart for RO

No chart data available.
  • RO:SW 257.50
  • 1D
  • 1M
  • 1Y
261.50
Interactive RO Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RO

Current P/E Ratio (ttm) 23.4986
Estimated P/E(12/2015) 18.5564
Relative P/E vs. SMI 1.2724
Earnings Per Share (CHF) (ttm) 10.9900
Est. EPS (CHF) (12/2015) 13.9170
Est. PEG Ratio 3.7397
Market Cap (M CHF) 221,246.31
Shares Outstanding (M) 160.00
30 Day Average Volume 30,499
Price/Book (mrq) 11.2042
Price/Sale (ttm) 4.6169
Dividend Indicated Gross Yield 3.10%
Cash Dividend (CHF) 8.0000
Dividend Ex-Date 03/05/2015
5 Year Dividend Growth 5.92%
Next Earnings Announcement 07/23/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RO

  • Revenue
  • Net Income (M/CHF)
  • Profit Margin (%)

Company Profile & Key Executives for RO

Roche Holding AG develops and manufactures pharmaceutical and diagnostic products. The Company produces prescription drugs in the areas of cardiovascular, infectious, autoimmune, and respiratory diseases, dermatology, metabolic disorders, oncology, transplantation, and the central nervous system.

Severin SchwanChief Executive OfficerAlan HippeChief Financial & IT Officer
Roland DiggelmannCOO:DiagnosticsGottlieb A KellerGeneral Counsel
More Company Profile & Key Executives for RO

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil